In total, approximately 30,000 adults of both sexes will be recruited for the study, which is expected to last approximately three months. Participants will receive an intramuscular injection of 100 micrograms of mRNA-1273 or a placebo on day 1 and day 29. The trial will be conducted at 87 sites in the United States.
If the trial goes ahead on time, he would keep Moderna’s promise to start in July. Earlier this month, there was speculation that the phase 3 trial would be delayed due to the company’s changes to the testing protocol. Moderna and government health officials have also been reported to disagree on various aspects of the tests, although both parties argue that this is not the case.
The company, which is relatively new compared to its larger peers who are also developing candidate coronavirus vaccines, has never conducted a clinical trial of this size. And unlike many of his rivals, he never had a single approved product.
However, the results he has published from previous trials on mRNA-1273 are very encouraging, and the vaccine candidate is advancing fairly quickly in the clinical trial process. As a result, many health experts and industry observers believe Moderna is likely to be the first to market a coronavirus vaccine.
Investors seem to be cheered by this latest news. In the middle of the afternoon on Tuesday, Moderna shares rose 4%, considerably outpacing gains in the broader stock market.